Dr. Borad on the SARAH and SIRveNIB Studies in Hepatocellular Carcinoma

Dr. Bendell on FDA Approval of Regorafenib in Liver CancerПодробнее

Gastrointestinal Cancer | Mitesh BoradПодробнее

Global treatment pattern variations in HCCПодробнее

Hepatocellular Carcinoma: 7 Most Common causes| RISK FACTOR FOR HCC| Liver cancer-Dr Jyoti BalaПодробнее

Improving Outcomes in Intermediate to Advanced HCC: A Multidisciplinary Tumor BoardПодробнее

Considering Adverse Events in Hepatocellular CarcinomaПодробнее

HCC Whiteboard #1: The Epidemiology of Hepatocellular Carcinoma and Current Standard of CareПодробнее

SIRT Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB Study)Подробнее

Dr. Finn on Studies of Pembrolizumab in Hepatocellular CarcinomaПодробнее

BSIRT/ IRJ Journal Club: SIRT Y90 SARAH trialПодробнее

Treatment of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma | RTCL.TVПодробнее

Effective Treatments for Cancer | Mitesh BoradПодробнее

Direct-Acting Antivirals in Patients with Hepatocellular CarcinomaПодробнее

Dr. Kennedy on Next Steps With SIRFLOX Trial in Liver-Metastatic CRCПодробнее

Hepatocellular carcinoma / Hepatoma - CT immaging - RadiologyПодробнее

Managing Systemic Treatment in Liver CancerПодробнее

Hepatocellular Carcinoma - Molecular Approaches to TreatmentПодробнее

Update on Screening for Hepatocellular Carcinoma (HCC)Подробнее

Viruses Causing Cancer | Mitesh BoradПодробнее